Michael U Callaghan

9PUBLICATIONS
20CO-AUTHORS
Immunogenetics (incl. genetic immunology)Epidemiological methodsHaematologyMajor global burdens of diseaseCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 28, 2021
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.

Christine Kempton, Peter Trask, Aric Parnes

|Sep 24, 2020
Bortezomib treatment of steroid-refractory Evans syndrome in children.

Serina B Beydoun, Yogindra Persaud, Jennifer Lafferty

|Mar 07, 2020
Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres.

Lynn M Malec, Stacy E Croteau, Michael U Callaghan

|Apr 25, 2019
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Johnny Mahlangu, Johannes Oldenburg, Michael U Callaghan

|Feb 15, 2019
Concurrent homozygous sickle-cell disease and severe haemophilia A: Thromboelastography profiles.

Ahmar U Zaidi, Latha Rao, Michael U Callaghan

|Nov 15, 2018
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Johannes Oldenburg, Johnny N Mahlangu, Willem Bujan

Pageof 2

Frequent Collaborators

4 joint publications

Johnny N Mahlangu

3 joint publications

Rebecca Kruse-Jarres

2 joint publications

Johannes Oldenburg

2 joint publications

Sylvia von Mackensen